Ritedose Has Been Acquired By Humanwell Healthcare and AGIC Capital

Monday, October 2, 2017


William Blair acted as the lead financial advisor to the Ritedose Corporation, a portfolio company of Olympus Partners, in connection with its sale to Humanwell Healthcare and AGIC Capital. The transaction closed on September 13 and represents one of 14 William Blair transactions in the pharmaceutical services space completed in the past 12 months. William Blair advised Ritedose on the transaction in conjunction with its Asian affiliate, BDA Partners1.

Transaction Highlights

  • Deep sector expertise: Ritedose was attracted to William Blair’s extensive knowledge of the contract manufacturing and biopharmaceutical space, significant transaction experience with other outsourced pharmaceutical services companies, and strong relationships with potential buyers.
  • Process and execution excellence: William Blair designed and executed a highly competitive sale process with outreach to a global audience of highly interested strategic and financial buyers. This process drove a strong competitive dynamic, yielding an outstanding outcome and finding the right partner at a premium multiple for Ritedose. 
  • Trusted guidance: William Blair’s transaction team was deeply involved in each step of the transaction process, including close collaboration with Ritedose in developing marketing materials, coordinating due diligence with multiple parties, and negotiating key contract terms.

About the Companies

Ritedose is the leading manufacturer of unit-dose sterile pharmaceutical products in the United States using Blow-Fill-Seal technology. The company produces about 1.0 billion units annually for the respiratory and ophthalmic markets through its contract manufacturing business and operating subsidiary Ritedose Pharmaceuticals. The Ritedose Corporation was founded in 1995 and is based in Columbia, South Carolina.

Humanwell Healthcare is a fully integrated China-based healthcare solutions provider. Since its establishment in 1993, Humanwell has endeavored to bring safe and effective medicines to the world through the quality of its products and integrity of its people.

Founded in 2015, AGIC Capital is an Asian buyout investor focused on European and U.S. middle-market companies in high-growth industries. AGIC invests in companies with high-value-add technologies that significantly increase industrial productivity and efficiency, enable new applications and manufacturing methods, and drive innovation for industrial products and solutions.

Founded in 1988, Olympus Partners is a private equity firm focused on providing equity capital for middle-market management buyouts and for companies needing capital for expansion. Olympus is an active, long-term investor across a broad range of industries, including restaurants, consumer products, healthcare services, financial services, and business services. Olympus manages in excess of $5.5 billion on behalf of corporate pension funds, endowment funds, and state-sponsored retirement programs.

1William Blair made a minority investment in and entered into a strategic alliance with BDA Partners in order to offer clients our collective global reach.

Learn more about our healthcare investment banking expertise

News Alerts

Stay connected to your favorite publications and news features.

Subscribe Now